James William  Burns net worth and biography

James Burns Biography and Net Worth

https://www.linkedin.com/in/jackie-fouse-a90b811aa of Agios Pharmaceuticals
Mr. Burns serves as chief legal officer and joined Agios in 2016 as a senior attorney and the company’s first head of compliance. He has more than 15 years of legal and compliance experience in the pharmaceutical industry. Prior to Agios, Mr. Burns held roles of increasing responsibility at EMD Serono, culminating in his position as associate general counsel for commercial. He began his legal career as a corporate attorney at Testa, Hurwitz and Thibeault and Goodwin Procter. Mr. Burns holds a B.A. degree from Seton Hall University and a J.D. from Seton Hall University School of Law.

What is James William Burns' net worth?

The estimated net worth of James William Burns is at least $1.45 million as of March 5th, 2024. Mr. Burns owns 34,518 shares of Agios Pharmaceuticals stock worth more than $1,445,959 as of December 18th. This net worth approximation does not reflect any other assets that Mr. Burns may own. Additionally, Mr. Burns receives an annual salary of $660,330.00 as https://www.linkedin.com/in/jackie-fouse-a90b811aa at Agios Pharmaceuticals. Learn More about James William Burns' net worth.

How old is James William Burns?

Mr. Burns is currently 46 years old. There are 9 older executives and no younger executives at Agios Pharmaceuticals. The oldest executive at Agios Pharmaceuticals is Dr. Tak Wah Mak D.Sc., FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 78 years old. Learn More on James William Burns' age.

What is James William Burns' salary?

As the https://www.linkedin.com/in/jackie-fouse-a90b811aa of Agios Pharmaceuticals, Inc., Mr. Burns earns $660,330.00 per year. There are 2 executives that earn more than Mr. Burns. The highest earning executive at Agios Pharmaceuticals is Mr. Brian M. Goff M.B.A., CEO & Director, who commands a salary of $1,230,000.00 per year. Learn More on James William Burns' salary.

How do I contact James William Burns?

The corporate mailing address for Mr. Burns and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on James William Burns' contact information.

Has James William Burns been buying or selling shares of Agios Pharmaceuticals?

James William Burns has not been actively trading shares of Agios Pharmaceuticals over the course of the past ninety days. Most recently, James William Burns sold 2,642 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a transaction totalling $86,049.94. Following the completion of the sale, the insider now directly owns 34,518 shares of the company's stock, valued at $1,124,251.26. Learn More on James William Burns' trading history.

Who are Agios Pharmaceuticals' active insiders?

Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Agios Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 17 times. They sold a total of 76,341 shares worth more than $2,120,143.90. The most recent insider tranaction occured on December, 11th when Director David Scadden sold 200 shares worth more than $9,256.00. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.

Information on this page was last updated on 12/11/2024.

James William Burns Insider Trading History at Agios Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/5/2024Sell2,642$32.57$86,049.9434,518View SEC Filing Icon  
1/24/2024Sell1,708$21.64$36,961.1230,378View SEC Filing Icon  
1/9/2024Sell1,163$22.99$26,737.3726,336View SEC Filing Icon  
8/17/2023Sell6,395$26.28$168,060.6023,890View SEC Filing Icon  
6/30/2023Sell1,707$28.36$48,410.5230,285View SEC Filing Icon  
See Full Table

James William Burns Buying and Selling Activity at Agios Pharmaceuticals

This chart shows James William Burns's buying and selling at Agios Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals logo
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $41.89
Low: $40.50
High: $42.28

50 Day Range

MA: $50.09
Low: $38.17
High: $61.64

2 Week Range

Now: $41.89
Low: $20.96
High: $62.58

Volume

269,089 shs

Average Volume

719,164 shs

Market Capitalization

$2.39 billion

P/E Ratio

3.69

Dividend Yield

N/A

Beta

0.8